Better Buy: CRISPR vs. Fulgent Genetics

CRISPR Therapeutics (NASDAQ: CRSP) and Fulgent Genetics (NASDAQ: FLGT) operate at different ends of the scientific gene pool. CRISPR, named for the Nobel Prize-winning CRISPR gene-editing technique, is a clinical-stage biotech company that is looking for gene-editing therapies to treat blood disorders, cancer, diabetes, and other diseases. Fulgent Genetics, meanwhile, is a genetics testing provider that uses next-generation sequencing (NGS) to study genetic variations connected with diseases or other biological phenomena.

One similarity they do share is their shares' meteoric rise over the past year. CRISPR's have climbed more than 150%, while Fulgent's have skyrocketed 470%. Which looks to be the best buy right now?

Image source: Getty Images. 

Continue reading

Source Fool.com